ASX Health Stocks: China likes Uscom device, includes it in national emergency guidelines
Health & Biotech
Health & Biotech
Medical device company Uscom (ASX:UCM) said that it has been included in the national emergency medicine guidelines for acute heart failure in China.
The guidelines were authored by various Chinese organisations including The Chinese Society of Emergency Medicine and The Professional Committee of Emergency Medicine of the People’s Liberation Army.
The USCOM 1A device is a non-invasive ultrasonic haemodynamic monitor which validates heart failure and provides precise care for cardiovascular abnormalities.
The device has been established in a number of other practice guidelines around the world, with its non-invasive nature and high accuracy making it particularly useful for application in emergency departments.
In China, heart failure has an incidence rate of around 1.1%, and occurs in a reported 12.1m million patients.
The average cost of heart failure (HF) care per year is estimated at more than US$4,400 per patient, making HF a serious public health burden in the country.
Recently, the PRC Ministry of Health and Medical Commission has recommended the USCOM 1A device for the treatment of severe COVID.
“This recognition by the collaborative colleges of emergency medicine in China is important for Uscom as we further consolidate our role in clinical practice across China,” said executive chairman of Uscom, Professor Rob Phillips.
“These clinical practice guidelines reflect years of data and clinician confidence, and confirm the scientific leadership that Uscom has established with its products worldwide.”
Immutep (ASX:IMM) has just announced an investigator-initiated Phase 2 Trial evaluating its LAG-3 candidate, Eftilagimod Alpha (Efti), in soft tissue sarcoma.
The study will be conducted by the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland.
Under the agreement, the Institute will fund the study primarily with an approved grant from the Polish government of €1.5M (~$2.2m).
Immutep on the other hand will contribute to the study by providing efti at no cost to the Institute, and will also support the trial from a technical perspective.
There is currently a lack of standard of care available for soft tissue sarcoma, a rare and difficult-to-treat disease. Efti’s novel mechanism of action offer potential to enhance the anti-tumour responses for these patients.
“This latest expansion of the efti pipeline is further evidence of the increased interest from a variety of interested parties to investigate the broad potential of efti to improve patient outcomes in yet another cancer indication and treatment regimen,” said Immutep CEO, Marc Voigt.